How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.com18F-FDG PET/CT in Gastric Cancer
Description:
PET and PET/CT imaging remains promising, and with current and further improvements, PET and PET/CT imaging may make the diagnosis and evaluation of gastric cancer more standardized and accurate.
Sponsor:
Sohag UniversityGovernment Study Link:
NCT07528131 - Click here to see study onClinicalTrials.gov
FDG
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Glucose Transport
Ligand Class: Small Molecules
Inclusion
- Patients with gastric cancer either operated or not
- Patients diagnosed as Gastric Cancer on surgically resected specimens.
- Patients with gastric and extragastric metastasis.
Exclusion
Exclusion Criteria Not Yet Provided
Share your feedback
Help us improve your experience